SCHEMBL7340685

SCHEMBL7340685

CC(C)(C)OC(=O)C(N)Cc1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.47
CTSK P43235 1/20 0.47
SLC7A5 Q01650 3/20 0.44
MME P08473 2/20 0.43
ACACB O00763 1/20 0.40
DPP4 P27487 1/20 0.40
FAP Q12884 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
CACNA1B Q00975 1/20 0.39
EPHX1 P07099 1/20 0.39
LTA4H P09960 1/20 0.39
ALPI P09923 1/20 0.39
PKM P14618 1/20 0.39
PTGS1 P23219 1/20 0.39
XIAP P98170 1/20 0.39
CYP3A4 P08684 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10562986 1.00 CTSS (0.47) CTSSCTSKSLC7A5MMEACACB
SCHEMBL17978113 0.86 SLC7A5 (0.45) SLC7A5ACACBDPP4FAPDPP8
SCHEMBL3203564 0.86 SLC7A5 (0.45) SLC7A5DPP4DPP8DPP9DPP7
SCHEMBL630703 0.86 SLC7A5 (0.57) CTSSCTSKSLC7A5
SCHEMBL17978114 0.86 SLC7A5 (0.45) SLC7A5ACACBDPP4FAPDPP8
SCHEMBL594571 0.86 SLC7A5 (0.57) CTSSCTSKSLC7A5
SCHEMBL7464405 0.86 SLC7A5 (0.57) CTSSCTSKSLC7A5
SCHEMBL6666822 0.86 SLC7A5 (0.45) SLC7A5DPP4DPP8DPP9DPP7
SCHEMBL25320423 0.84 CYP3A4 (0.55) SLC7A5ACACBDPP4LTA4HCYP3A4
SCHEMBL20235896 0.84 TP53 (0.45) SLC7A5ACACBDPP4FAPDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114728914-B Dioxopiperazine derivative, preparation method thereof and application thereof in medicines 深圳信立泰药业股份有限公司 2023-05-12 CN disclosed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 CTSS 128/4885CTSK 48/4885SLC7A5 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.